Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells.

Segaliny AI, Cheng JL, Farhoodi HP, Toledano M, Yu CC, Tierra B, Hildebrand L, Liu L, Liao MJ, Cho J, Liu D, Sun L, Gulsen G, Su MY, Sah RL, Zhao W.

EBioMedicine. 2019 Jul;45:39-57. doi: 10.1016/j.ebiom.2019.06.047. Epub 2019 Jul 4.

PMID:
31281099
2.

Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders.

Riazifar M, Mohammadi MR, Pone EJ, Yeri A, Lässer C, Segaliny AI, McIntyre LL, Shelke GV, Hutchins E, Hamamoto A, Calle EN, Crescitelli R, Liao W, Pham V, Yin Y, Jayaraman J, Lakey JRT, Walsh CM, Van Keuren-Jensen K, Lotvall J, Zhao W.

ACS Nano. 2019 Jun 25;13(6):6670-6688. doi: 10.1021/acsnano.9b01004. Epub 2019 May 29.

PMID:
31117376
3.

Functional TCR T cell screening using single-cell droplet microfluidics.

Segaliny AI, Li G, Kong L, Ren C, Chen X, Wang JK, Baltimore D, Wu G, Zhao W.

Lab Chip. 2018 Dec 4;18(24):3733-3749. doi: 10.1039/c8lc00818c.

PMID:
30397689
4.

Mechanoresponsive stem cells to target cancer metastases through biophysical cues.

Liu L, Zhang SX, Liao W, Farhoodi HP, Wong CW, Chen CC, Ségaliny AI, Chacko JV, Nguyen LP, Lu M, Polovin G, Pone EJ, Downing TL, Lawson DA, Digman MA, Zhao W.

Sci Transl Med. 2017 Jul 26;9(400). pii: eaan2966. doi: 10.1126/scitranslmed.aan2966.

5.

Bone Morphogenetic Protein 2 and Transforming Growth Factor β1 Inhibit the Expression of the Proinflammatory Cytokine IL-34 in Rheumatoid Arthritis Synovial Fibroblasts.

Chemel M, Brion R, Segaliny AI, Lamora A, Charrier C, Brulin B, Maugars Y, Le Goff B, Heymann D, Verrecchia F.

Am J Pathol. 2017 Jan;187(1):156-162. doi: 10.1016/j.ajpath.2016.09.015. Epub 2016 Nov 17.

6.

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers.

Ségaliny AI, Tellez-Gabriel M, Heymann MF, Heymann D.

J Bone Oncol. 2015 Jan 23;4(1):1-12. doi: 10.1016/j.jbo.2015.01.001. eCollection 2015 Mar. Review.

7.

IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization.

Ségaliny AI, Brion R, Brulin B, Maillasson M, Charrier C, Téletchéa S, Heymann D.

Cytokine. 2015 Dec;76(2):170-181. doi: 10.1016/j.cyto.2015.05.029. Epub 2015 Jun 19.

PMID:
26095744
8.

Syndecan-1 regulates the biological activities of interleukin-34.

Segaliny AI, Brion R, Mortier E, Maillasson M, Cherel M, Jacques Y, Le Goff B, Heymann D.

Biochim Biophys Acta. 2015 May;1853(5):1010-21. doi: 10.1016/j.bbamcr.2015.01.023. Epub 2015 Feb 4.

9.

Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment.

Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D.

Int J Cancer. 2015 Jul 1;137(1):73-85. doi: 10.1002/ijc.29376. Epub 2014 Dec 13.

10.

The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro.

Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, Lambert G.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):246-52. doi: 10.1161/ATVBAHA.109.200196. Epub 2009 Dec 3.

Supplemental Content

Loading ...
Support Center